| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11,6 M € | +7.9% | 10,7 M € | — | — | — | — | 0,0 € | -100.0% | 1,7 M € | — | — | ||||||||
| Gross margin | 5,9 M € | +14.1% | 5,2 M € | +11.9% | 4,7 M € | -4.9% | 4,9 M € | +12.9% | 4,3 M € | +57.2% | 2,8 M € | -57.9% | 6,5 M € | +893.7% | 658,6 k € | +213.4% | -581,0 k € | +2.6% | -596,4 k € | |
| EBITDA | 1,3 M € | +3.5% | 1,2 M € | +10.5% | 1,1 M € | -31.5% | 1,6 M € | +26.6% | 1,3 M € | +50.0% | 862,5 k € | -82.1% | 4,8 M € | +1584.6% | -324,8 k € | +67.9% | -1,0 M € | -12.0% | -902,3 k € | |
| Operating profit | 523,4 k € | +20.6% | 434,2 k € | +29.1% | 336,3 k € | -58.2% | 804,2 k € | +21.8% | 660,3 k € | +100.2% | 329,8 k € | -92.1% | 4,2 M € | +632.6% | -783,8 k € | +43.2% | -1,4 M € | -7.3% | -1,3 M € | |
| Profit/loss | 585,1 k € | +2.2% | 572,6 k € | +124.9% | 254,6 k € | -67.5% | 783,7 k € | +52.3% | 514,4 k € | +8.7% | 473,1 k € | -88.4% | 4,1 M € | +891.6% | -514,7 k € | +63.3% | -1,4 M € | -10.8% | -1,3 M € | |
| Equity | 4,9 M € | +13.5% | 4,3 M € | +15.2% | 3,8 M € | +7.3% | 3,5 M € | +28.7% | 2,7 M € | +23.2% | 2,2 M € | +27.2% | 1,7 M € | -55.4% | 3,9 M € | +242.5% | 1,1 M € | -28.4% | 1,6 M € | |
| Total assets | 6,9 M € | +20.8% | 5,7 M € | -2.1% | 5,8 M € | -12.5% | 6,7 M € | +31.8% | 5,0 M € | +27.1% | 4,0 M € | -55.4% | 8,9 M € | +64.4% | 5,4 M € | +325.0% | 1,3 M € | -22.3% | 1,6 M € | |
| Cash | 717,7 k € | -12.8% | 822,8 k € | -54.9% | 1,8 M € | +73.2% | 1,1 M € | +303.8% | 261,0 k € | -25.9% | 352,0 k € | -35.6% | 547,0 k € | -62.5% | 1,5 M € | +1964.8% | 70,6 k € | -51.9% | 146,9 k € | |
| Debts | 1,9 M € | +44.3% | 1,3 M € | -34.5% | 2,1 M € | -32.7% | 3,0 M € | +31.3% | 2,3 M € | +32.7% | 1,7 M € | -73.2% | 6,5 M € | +1578.7% | 389,4 k € | +184.8% | 136,7 k € | +170.1% | 50,6 k € | |
| Staff | 36,3 | 35,5 | 34,2 | 34,7 | 31,6 | 22,4 | 15,5 | 11,9 | — | 5,2 | ||||||||||
Private limited company · Gent · incorporated on 02/09/2015 · 36,3 ETP
Private limited company profitable and well capitalised. Cash position declining (-12.8%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
ORIONIS BIOSCIENCES is a Private limited company incorporated in 2015. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Gent. It employs on average 36,3 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette